Table 1.
Clinical characteristics and baseline laboratory results
| Patients in PK analysis, n | |
| Female, n | 28 (35.9%) |
| White race, n | 72 (92.3%) |
| Weight, kg (median, IQR) | 41 (28–56.8) |
| < 30 kg, n | 23 (30%) |
| Age at first infusion, years (mean, SD) | 13 (3.7) |
| < 10 years old, n | 15 (19.2%) |
| Disease duration, days (median, IQR) | 49 (18–382) |
| Infliximab dose, mg/kg (median, IQR) | 6.1 (5.2–7.1) |
| Crohn’s location | |
| Ileal only: colon only: ileocolonic | 9:7:62 |
| Crohn’s behavior | |
| Inflammatory | 66 |
| Stricturing | 7 |
| Penetrating | 4 |
| Both stricturing/penetrating | 1 |
| Perianal fistula, n | 12 (15.4%) |
| wPCDAI (median, IQR) | 38 (20–65) |
| Erythrocyte sedimentation rate, mm/h (median, IQR) | 15 (8–38) |
| CRP, mg/dL (median, IQR) | 1.0 (0.29–2.4) |
| Serum albumin, g/dL (mean, SD) | 3.3 (0.6) |
| Neutrophil CD64 activity ratio, MFI (median, IQR) | 6.5 (6–7.1) |
| Fecal calprotectin, μg/g (median, IQR) | 1611 (994–2501) |
IQR, interquartile range; MFI, mean fluorescence intensity; PK, pharmacokinetic; wPCDAI, weighted pediatric CD activity index.